Kunxian for the Treatment of Rheumatoid Arthritis
Primary Purpose
Rheumatoid Arthritis
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Kunxian Capsule
Methotrexate
Sponsored by
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring Kunxian Capsule, efficacy, rheumatoid arthritis, Methotrexate
Eligibility Criteria
Inclusion Criteria:
- Patients who understand the study protocol and sign the informed consent;
- Fulfill the 1987 or 2010 ACR classification criteria for RA;
- Male or female patients, age ranged from 40-70;
- Male or female who do not plan to have more child,or per-menopausal or menopausal women;
- Patients with mild or moderate disease activity, ie, whose DAS28 ranged from 3.2-5.1(ie, ESR>28mm/h,or patients who have 1-5 swollen joints as well as 1-5 tender joints);
- Without severe systemic disorders,such as severe pericardial effusion,pulmonary interstitial fibrosis,renal tubual acidosis,atrophic gastritis,autoimmune liver disease etc.
- Not included in any drug trial 1 month before enrollment
Exclusion Criteria:
- Pregnant woman or women who are preparing to pregnant or breast feeding;
- Patients with active liver diseases or elevated liver enzymes eg, the ALT and/or AST is higher than 1.5 of the upper limit of normal range;
- Patients with renal function abnormality,eg,serum creatinin higher than the upper limit of normal range;
- White blood cell count less than 3.0×109/L,or with anemia(hemoglobin level lower than 80g/L),or platelet count less than 80×109/L,or with other hematological diseases;
- Patients with chronic gastrointestinal diseases;
- Patients with un-controlled hypertension,metabolic diseases such as diabetes;
- History of malignant tumor or has malignant tumor at present;
- With acute and/or chronic contagious diseases;
- Severe arrhythmia on ECG test;
- History of adverse reaction with Kunxian capsule,or Tripterygium wilfordii Hook F.,methotrexate or medications contain kunminshanhaitang ingredient;
- History of psychiatric diseases or alcoholism or drug abuse;
- Having been diagnosed to have systemic rheumatic diseases;
- Ever taken immunosuppressive agents or biological agents or Tripterygium wilfordii Hook F or medications contain kunminshanhaitang ingredient in recent 3 months;
- Had ever taken methotrexate or Kunxian capsule for more than 12 weeks but could not control the arthritis under remission;
- With other conditions that are considered to be inconsistent with the inclusion criteria according to the investigators.
Sites / Locations
- the Affiliated Hospital to Bangbu Medical UniversityRecruiting
- The First Affiliated Hospital of Bengbu Medical CollegeRecruiting
- AnHui provincial hospitalRecruiting
- Nanfang HospitalRecruiting
- The Third Affiliated Hospital to SUN YAT-SEN UniversityRecruiting
- The First Affiliated Hospital of Harbin Medcial UniversityRecruiting
- The first affiliated hospital of Zhengzhou UniversityRecruiting
- Minda Hospital of Hubei ProvinceRecruiting
- Jiangsu Province HospitalRecruiting
- Affiliated Hospital of Nantong UniversityRecruiting
- Xijing HospitalRecruiting
- the Affiliated Hospital of Kunming Medical UniversityRecruiting
- Guang'anmen Hospital,China Academy of Chinese Medical SciencesRecruiting
- Peking Union Medical College HospitalRecruiting
- Guang Hua hospitalRecruiting
- Zhongshan Hospital Fudan UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Kunxian capsule group
Methotrexate group
Arm Description
Intervention: Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo.
Intervention: Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks.
Outcomes
Primary Outcome Measures
Proportion of patients with ACR 20/50/70
the percentage of patients who have ACR 20,50 and 70 treatment response after treated with Kunxian Capsule and Methotrexate for 24 weeks
Secondary Outcome Measures
Proportion of patients whose DAS28 score less than 2.6 or 3.2 after treated with Kunxian Capsule and Methotrexate
Percentage of patients whose DAS28 could be lower than 3.2 or 2.6 after treated with Kunxian Capsule and Methotrexate for 24 weeks
Proportion of patients with adverse events in the Kunxian Capsule treatment group
The adverse events profile such as gastrointestinal tract adverse events, the percentage of patients with gonodal gland toxicities, liver function abnormalities, hematological abnormalities,skin rashes etc in patients treated with Kunxian Capsule will be analyzed and compared with the adverse events in patients treated with Methotrexate during the same time period.
Full Information
NCT ID
NCT02764515
First Posted
March 26, 2016
Last Updated
March 8, 2017
Sponsor
Chinese SLE Treatment And Research Group
Collaborators
CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group, CHINESE RHEUMATISM DATA CENTER
1. Study Identification
Unique Protocol Identification Number
NCT02764515
Brief Title
Kunxian for the Treatment of Rheumatoid Arthritis
Official Title
Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Unknown status
Study Start Date
September 2015 (undefined)
Primary Completion Date
September 2017 (Anticipated)
Study Completion Date
November 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese SLE Treatment And Research Group
Collaborators
CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group, CHINESE RHEUMATISM DATA CENTER
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a multicenter, randomized, double blind, double-dummy and controlled clinical trial aimed to compare the clinical efficacy and safety of Kunxian Capsule, a compound of Chinese traditional medicine, and the active comparator,Methotrexate for the treatment of rheumatoid arthritis. The primary end-point is that Kunxian Capsule is not inferior to Methotrexate both in efficacy and safety.
Detailed Description
This is a prospective, multicenter, randomized, double blind, double-dummy and controlled clinical trial.The goal is to compare the clinical efficacy and safety of Kunxian Capsule, a compound of 4 ingredients of Chinese herb-derived medication, and the active comparator, Methotrexate for the treatment of mild to moderate active rheumatoid arthritis.This study is basically non-inferiority in design, so 428 subjects will be enrolled. All subjects need to fulfill the inclusion criteria and without exclusion criteria. Subjects are randomized into the Kunxian Capsule treatment group and Methotrexate treatment group.The dosage of Kunxian Capsule used in this study is 0.6g twice daily and the methotrexate dosage is 10mg per week. All subjects will take the medication for 24 weeks. Diclofenic is used as the salvage therapy in case patients experience joint pain. The primary end-point is the proportion of patients who could achieve disease remission or low disease activity treated with Kunxian Capsule and Methotrexate. All patients will be followed at week 2,4,12 and 24 after screening. Baseline information for disease activity measures such as DAS28 score,CDAI score, SDAI score, ACR20, ACR50, ACR70 improvement, HAQ score, patient's VAS score for pain, and lab tests such as CRP, ESR, RF, CCP, blood and urine routine tests, liver as well as renal function tests were collected and recorded. All these measures are performed at each follow-up visit except RF and CCP. In addition, any adverse events or withdrawal happened during each visit will be recorded for data analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis
Keywords
Kunxian Capsule, efficacy, rheumatoid arthritis, Methotrexate
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
428 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Kunxian capsule group
Arm Type
Experimental
Arm Description
Intervention:
Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo.
Arm Title
Methotrexate group
Arm Type
Active Comparator
Arm Description
Intervention:
Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks.
Intervention Type
Drug
Intervention Name(s)
Kunxian Capsule
Other Intervention Name(s)
Tripterygium wilfordii Hook F.
Intervention Description
Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
Intervention Type
Drug
Intervention Name(s)
Methotrexate
Other Intervention Name(s)
jiaandieling
Intervention Description
the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
Primary Outcome Measure Information:
Title
Proportion of patients with ACR 20/50/70
Description
the percentage of patients who have ACR 20,50 and 70 treatment response after treated with Kunxian Capsule and Methotrexate for 24 weeks
Time Frame
24 weeks from baseline
Secondary Outcome Measure Information:
Title
Proportion of patients whose DAS28 score less than 2.6 or 3.2 after treated with Kunxian Capsule and Methotrexate
Description
Percentage of patients whose DAS28 could be lower than 3.2 or 2.6 after treated with Kunxian Capsule and Methotrexate for 24 weeks
Time Frame
24 weeks from baseline
Title
Proportion of patients with adverse events in the Kunxian Capsule treatment group
Description
The adverse events profile such as gastrointestinal tract adverse events, the percentage of patients with gonodal gland toxicities, liver function abnormalities, hematological abnormalities,skin rashes etc in patients treated with Kunxian Capsule will be analyzed and compared with the adverse events in patients treated with Methotrexate during the same time period.
Time Frame
24 weeks from baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who understand the study protocol and sign the informed consent;
Fulfill the 1987 or 2010 ACR classification criteria for RA;
Male or female patients, age ranged from 40-70;
Male or female who do not plan to have more child,or per-menopausal or menopausal women;
Patients with mild or moderate disease activity, ie, whose DAS28 ranged from 3.2-5.1(ie, ESR>28mm/h,or patients who have 1-5 swollen joints as well as 1-5 tender joints);
Without severe systemic disorders,such as severe pericardial effusion,pulmonary interstitial fibrosis,renal tubual acidosis,atrophic gastritis,autoimmune liver disease etc.
Not included in any drug trial 1 month before enrollment
Exclusion Criteria:
Pregnant woman or women who are preparing to pregnant or breast feeding;
Patients with active liver diseases or elevated liver enzymes eg, the ALT and/or AST is higher than 1.5 of the upper limit of normal range;
Patients with renal function abnormality,eg,serum creatinin higher than the upper limit of normal range;
White blood cell count less than 3.0×109/L,or with anemia(hemoglobin level lower than 80g/L),or platelet count less than 80×109/L,or with other hematological diseases;
Patients with chronic gastrointestinal diseases;
Patients with un-controlled hypertension,metabolic diseases such as diabetes;
History of malignant tumor or has malignant tumor at present;
With acute and/or chronic contagious diseases;
Severe arrhythmia on ECG test;
History of adverse reaction with Kunxian capsule,or Tripterygium wilfordii Hook F.,methotrexate or medications contain kunminshanhaitang ingredient;
History of psychiatric diseases or alcoholism or drug abuse;
Having been diagnosed to have systemic rheumatic diseases;
Ever taken immunosuppressive agents or biological agents or Tripterygium wilfordii Hook F or medications contain kunminshanhaitang ingredient in recent 3 months;
Had ever taken methotrexate or Kunxian capsule for more than 12 weeks but could not control the arthritis under remission;
With other conditions that are considered to be inconsistent with the inclusion criteria according to the investigators.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
XINPING TIAN, MD
Phone
86-10-69158707
Email
tianxp6@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
HAIJUN FU, PHD
Phone
13601912507
Email
hadrian.fox@shcares.com.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
XIAOFENG ZENG, MD
Organizational Affiliation
Peking Union Medical College Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
XINPING TIAN, MD
Organizational Affiliation
Peking Union Medical College Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
the Affiliated Hospital to Bangbu Medical University
City
Bangbu
State/Province
Anhui
ZIP/Postal Code
233000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhijun Li, MD
Phone
13955289810
Email
zhijun.li@cstar.org.cn
First Name & Middle Initial & Last Name & Degree
Changhao Xie, MD
Phone
15255227208
Email
uglboy2002@126.com
Facility Name
The First Affiliated Hospital of Bengbu Medical College
City
Bengbu
State/Province
Anhui
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xin Wang, MD
Phone
86-13515529256
Email
273084414@qq.com
First Name & Middle Initial & Last Name & Degree
Zhijun Li, MD
Phone
86-13956955150
Email
lizhijundr@126.com
Facility Name
AnHui provincial hospital
City
Hefei
State/Province
Anhui
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Wang, MD
Phone
86-15055148790
Email
wang_liy@aliyun.com
First Name & Middle Initial & Last Name & Degree
Xiangpei Li, MD
Phone
86-13515605909
Email
13515605909@126.com
Facility Name
Nanfang Hospital
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinjun Zhao, MD
Phone
86-13710596450
Email
zhao7749@126.com
First Name & Middle Initial & Last Name & Degree
Min Yang, MD
Phone
86-13802911770
Email
minyanggz@163.com
Facility Name
The Third Affiliated Hospital to SUN YAT-SEN University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Linkai Fang, MD
Phone
86-13751889563
Email
fanglinkai1984@163.com
First Name & Middle Initial & Last Name & Degree
Jieruo Gu, MD
Phone
13922280820
Email
gujieruo@163.com
Facility Name
The First Affiliated Hospital of Harbin Medcial University
City
Haerbin
State/Province
Heilongjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juan Gao, MD
Phone
86-15304803480
Email
happygigi@163.com
First Name & Middle Initial & Last Name & Degree
Zhiyi Zhang, MD
Phone
86-13303608999
Email
zhangzhiyi2014@163.com
Facility Name
The first affiliated hospital of Zhengzhou University
City
Zhengzhou
State/Province
Henan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiameng Lu, MD
Phone
86-18637184930
Email
lujiameng2003@126.com
First Name & Middle Initial & Last Name & Degree
Shengyun Liu, MD
Phone
86-13837192659
Email
shengyun@medmail.com.cn
Facility Name
Minda Hospital of Hubei Province
City
Enshi
State/Province
Hubei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Linchong Su, MD
Phone
86-15571781515
Email
"linchongsu@126.com
First Name & Middle Initial & Last Name & Degree
Yang Xiang, MD
Phone
86-13607249969
Email
xiangy1961@yahoo.com.cn
Facility Name
Jiangsu Province Hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chengyin Li, MD
Phone
86-13914751367
Email
lcyzjf@hotmail.com
First Name & Middle Initial & Last Name & Degree
Miaojia Zhang, MD
Phone
86-13611505999
Email
miaojia_zhang@163.com
Facility Name
Affiliated Hospital of Nantong University
City
Nantong
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yunfei Xia, MD
Phone
15896275028
Email
xiayf1986@163.com
First Name & Middle Initial & Last Name & Degree
Zhanyun Da, MD
Phone
86-18962940001
Email
dazhanyun@163.com
Facility Name
Xijing Hospital
City
Xian
State/Province
Shanxi
ZIP/Postal Code
710032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhenbiao Wu, MD
Phone
13700235112
Email
ping.zhu@cstar.org.cn
First Name & Middle Initial & Last Name & Degree
Weitong Chen, MD
Phone
15771943030
Email
chenweitong0818@163.com
Facility Name
the Affiliated Hospital of Kunming Medical University
City
Kunming
State/Province
Yunnan
ZIP/Postal Code
650032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jian Xu, MD
Phone
13888566797
Email
jian.xu@cstar.org.cn
First Name & Middle Initial & Last Name & Degree
Shu Li, MD
Phone
15198785584
Email
gglis@126.com
Facility Name
Guang'anmen Hospital,China Academy of Chinese Medical Sciences
City
Beijing
ZIP/Postal Code
100010
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hailong Wang, MD
Phone
86-13810112190
Email
wang.hailong@139.com
First Name & Middle Initial & Last Name & Degree
Quan Jiang, MD
Phone
86-13901081632
Email
doctorjq@126.com
Facility Name
Peking Union Medical College Hospital
City
Beijing
ZIP/Postal Code
100032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xinping Tian, MD
Phone
86-13691165939
Email
tianxp6@126.com
First Name & Middle Initial & Last Name & Degree
Shi Rong, MD
Phone
86-13601248311
Email
rongshipumch@126.com
First Name & Middle Initial & Last Name & Degree
XInping Tian, MD
Facility Name
Guang Hua hospital
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaolin Yang, MD
Phone
86-13701816768
Email
lindayoung365@hotmail.com
First Name & Middle Initial & Last Name & Degree
Dongyi He, MD
Phone
021-62805833
Email
dongyihe@medmail.com.cn
Facility Name
Zhongshan Hospital Fudan University
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huiyong Chen, MD
Phone
86-13817629793
Email
zsneike@163.com
First Name & Middle Initial & Last Name & Degree
Lindi Jiang, MD
Phone
86-13701973875
Email
jianglindi@medmail.com.cn
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Kunxian for the Treatment of Rheumatoid Arthritis
We'll reach out to this number within 24 hrs